PDF(Pubmed)
Abstract：
UNASSIGNED: This retrospective review assesses the efficacy and safety of low-dose triamcinolone (1mg/cc) added to hyaluronic acid fillers to decrease swelling after infraorbital injection.
UNASSIGNED: This retrospective analysis includes 447 patients who underwent 706 infraorbital hyaluronic acid filler treatments from April 2013 to March 2020 by a single injector. Short-term post-procedural swelling (≤2 weeks) was assessed through follow-up phone calls, which were documented in patient charts. The effect of triamcinolone, filler type, volume, and patient characteristics on the rate of post-procedure swelling were analyzed.
UNASSIGNED: Swelling after infraorbital hyaluronic acid filler occurred in over half of the patients (51%, 103/202), but significantly decreased (23%, 29/124) when 1mg/cc of triamcinolone was mixed with the filler (x2[1, N=326]=24.296, p<0.00001). The incidence of swelling was directly correlated with the amount of hyaluronic acid filler injected (37% ≤ 0.55cc, 51% 0.56-1cc, and 60% >1cc) [x2[1, N=95]=3.9231, p=.048]. There was no significant difference in patient age, sex, Fitzpatrick skin type, or history of allergies on incidence of post-procedure swelling. Adverse events were limited to expected injection-site reactions, and there were no reports of hypopigmentation or atrophy from the addition of triamcinolone.
UNASSIGNED: This is a retrospective study that used patient reporting for short-term post procedure swelling.
UNASSIGNED: This is the first retrospective study showing the safety and efficacy of a novel technique adding low-dose triamcinolone (1mg/cc) to hyaluronic acid filler to reduce post-procedure swelling within the first few weeks following infraorbital injection. Additionally, using lower volumes is also effective at reducing post-procedure swelling. Larger, randomized, controlled trials are needed to support our findings.
UNASSIGNED: This retrospective analysis includes 447 patients who underwent 706 infraorbital hyaluronic acid filler treatments from April 2013 to March 2020 by a single injector. Short-term post-procedural swelling (≤2 weeks) was assessed through follow-up phone calls, which were documented in patient charts. The effect of triamcinolone, filler type, volume, and patient characteristics on the rate of post-procedure swelling were analyzed.
UNASSIGNED: Swelling after infraorbital hyaluronic acid filler occurred in over half of the patients (51%, 103/202), but significantly decreased (23%, 29/124) when 1mg/cc of triamcinolone was mixed with the filler (x2[1, N=326]=24.296, p<0.00001). The incidence of swelling was directly correlated with the amount of hyaluronic acid filler injected (37% ≤ 0.55cc, 51% 0.56-1cc, and 60% >1cc) [x2[1, N=95]=3.9231, p=.048]. There was no significant difference in patient age, sex, Fitzpatrick skin type, or history of allergies on incidence of post-procedure swelling. Adverse events were limited to expected injection-site reactions, and there were no reports of hypopigmentation or atrophy from the addition of triamcinolone.
UNASSIGNED: This is a retrospective study that used patient reporting for short-term post procedure swelling.
UNASSIGNED: This is the first retrospective study showing the safety and efficacy of a novel technique adding low-dose triamcinolone (1mg/cc) to hyaluronic acid filler to reduce post-procedure swelling within the first few weeks following infraorbital injection. Additionally, using lower volumes is also effective at reducing post-procedure swelling. Larger, randomized, controlled trials are needed to support our findings.
摘要：
UNASSIGNED：这项回顾性审查评估了将低剂量曲安奈德（1mg/cc）添加到透明质酸填充剂中以减轻眶下注射后肿胀的疗效和安全性。
UNASSIGNED：这项回顾性分析包括447例患者，这些患者从2013年4月至2020年3月接受了706次眼眶下透明质酸填充剂治疗。通过电话随访评估术后短期肿胀（≤2周），这些都记录在病人图表中。曲安奈德的作用，填料类型,volume,和患者特征对术后肿胀率进行了分析。
未经证实：超过一半的患者出现眶下透明质酸填充后肿胀（51%，103/202），但显著下降(23%，29/124），当1mg/cc曲安奈德与填料混合时（x2[1，N=326]=24.296，p<0.00001）。肿胀的发生率与注射的透明质酸填充剂的量直接相关（37％≤0.55cc，51%0.56-1cc，和60%>1cc)[x2[1，N=95]=3.9231，p=.048]。患者年龄无显著差异,性别,Fitzpatrick皮肤类型,或过敏史对术后肿胀的发生率。不良事件仅限于预期的注射部位反应，并且没有因添加曲安奈德而导致色素沉着不足或萎缩的报道。
UNASSIGNED：这是一项回顾性研究，使用患者短期术后肿胀报告。
UNASSIGNED：这是第一项回顾性研究，显示了一种新技术的安全性和有效性，该技术在透明质酸填充剂中添加了低剂量曲安奈德（1mg/cc），以减少术后肿胀。此外,使用较低的体积在减少术后肿胀也是有效的。较大,随机化，需要对照试验来支持我们的发现.
UNASSIGNED：这项回顾性分析包括447例患者，这些患者从2013年4月至2020年3月接受了706次眼眶下透明质酸填充剂治疗。通过电话随访评估术后短期肿胀（≤2周），这些都记录在病人图表中。曲安奈德的作用，填料类型,volume,和患者特征对术后肿胀率进行了分析。
未经证实：超过一半的患者出现眶下透明质酸填充后肿胀（51%，103/202），但显著下降(23%，29/124），当1mg/cc曲安奈德与填料混合时（x2[1，N=326]=24.296，p<0.00001）。肿胀的发生率与注射的透明质酸填充剂的量直接相关（37％≤0.55cc，51%0.56-1cc，和60%>1cc)[x2[1，N=95]=3.9231，p=.048]。患者年龄无显著差异,性别,Fitzpatrick皮肤类型,或过敏史对术后肿胀的发生率。不良事件仅限于预期的注射部位反应，并且没有因添加曲安奈德而导致色素沉着不足或萎缩的报道。
UNASSIGNED：这是一项回顾性研究，使用患者短期术后肿胀报告。
UNASSIGNED：这是第一项回顾性研究，显示了一种新技术的安全性和有效性，该技术在透明质酸填充剂中添加了低剂量曲安奈德（1mg/cc），以减少术后肿胀。此外,使用较低的体积在减少术后肿胀也是有效的。较大,随机化，需要对照试验来支持我们的发现.
